Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Nature

Volumn 550, Issue 7675, 2017, Pages 270-274

  Kong, Xiangjun ^a   Kuilman, Thomas ^a   Shahrabi, Aida ^a   Boshuizen, Julia ^a   Kemper, Kristel ^a   Song, Ji Ying ^a   Niessen, Hans W M ^b   Rozeman, Elisa A ^a   Foppen, Marnix H Geukes ^a   Blank, Christian U ^a   Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; ANTINEOPLASTIC AGENT; B RAF KINASE; JUNB PROTEIN, HUMAN; JUNB PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

CANCER; CELLS AND CELL COMPONENTS; DRUG; DRUG RESISTANCE; GENE EXPRESSION; GENOME; INHIBITOR; PHENOTYPE; PROTEIN; TUMOR;

ARTICLE; B CELL LYMPHOMA CELL; CANCER RESISTANCE; CELL CULTURE; CELL SURVIVAL; CRISPR-CAS9 SYSTEM; DNA DAMAGE; DRUG DEPENDENCE; EPITHELIAL MESENCHYMAL TRANSITION; LUNG CANCER CELL LINE; MELANOMA CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CRISPR CAS SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENE EDITING; GENETICS; HUMAN; KNOCKOUT MOUSE; LUNG TUMOR; MAPK SIGNALING; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EDITING; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, KNOCKOUT; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN-ACTIVATED PROTEIN KINASE 1; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROTO-ONCOGENE PROTEINS B-RAF; TRANSCRIPTION FACTORS;

EID: 85031288867     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24037     Document Type: Article

References (26)

1. Suda, K. et al. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 76, 292-299 (2012).
2. Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
3. Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240-256 (2015).
4. Thakur, M. D. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
5. Seifert, H. et al. Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. Melanoma Res. 26, 138-144 (2016).
6. Dietrich, S. et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J. Clin. Oncol. 31, e300-e303 (2013).
7. Dooley, A. J., Gupta, A. & Middleton, M. R. Ongoing response in BRAF V600E-mutant melanoma after cessation of intermittent vemurafenib therapy: A case report. Target. Oncol. 11, 557-563 (2016).
8. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
9. Kemper, K. et al. BRAF(V600E) kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep. 16, 263-277 (2016).
10. Hoek, K. S. & Goding, C. R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res. 23, 746-759 (2010).
11. Hoek, K. S. et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68, 650-656 (2008).
12. Wellbrock, C. & Arozarena, I. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res. 28, 390-406 (2015).
13. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
14. Verfaillie, A. et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat. Commun. 6, 6683 (2015).
15. Konieczkowski, D. J. et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4, 816-827 (2014).
16. Müller, J. et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat. Commun. 5, 5712 (2014).
17. Ramsdale, R. et al. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci. Signal. 8, ra82 (2015).
18. Riesenberg, S. et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat. Commun. 6, 8755 (2015).
19. Shin, S., Dimitri, C. A., Yoon, S.-O., Dowdle, W. & Blenis, J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 38, 114-127 (2010).
20. Kemper, K. et al. Intra- And inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104-1118 (2015).
21. Seghers, A. C., Wilgenhof, S., Lebbé, C. & Neyns, B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 22, 466-472 (2012).
22. Schreuer, M. et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: An open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 18, 464-472 (2017).
23. Harries, M. et al. Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. Eur. J. Cancer 60, 179-189 (2016).
24. Jain, T. & Bryce, A. Intermittent BRAF inhibition can achieve prolonged disease control in BRAF mutant melanoma. Cureus 7, e410 (2015).
25. Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- And NRAS-mutant malignancies. Cancer Discov. 4, 538-545 (2014).
26. Dooley, A. J., Gupta, A., Bhattacharyya, M. & Middleton, M. R. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther. Adv. Med. Oncol. 6, 262-266 (2014).